Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 How Companies Can Make the Most of Their Early Drug Development Stage | Contract Pharma

What are you searching for?

Sign in
Literature / Brochures

How Companies Can Make the Most of Their Early Drug Development Stage

Dean Knuth, Executive Director of Clinical Sciences

Background
Companies large and small face enormous risks during the crucial early drug development stages. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), major pharmaceutical and biotechnology companies spent $10.5 billion or 22% of total annual R&D costs on non-clinical research in 2011 — more than the total amount spent on Phase I and II activity combined. i While the failure rate tends to diff er for small molecules and biologics, the majority of development eff orts fail, with the rate generally falling between 60 and 90%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics